The company is developing an antigen found in most human cancers.
Sirona CEO Howard Verrico said vaccines using these antigens have the potential to treat and prevent many forms of cancer including breast, lung, colon and prostate cancer.
"Using our proprietary chemistry technology, we have been able to tap into this challenging chemistry towards developing a stable antigen molecule," Verrico said.